{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/sleep-disorders-shift-work-jet-lag/how-up-to-date-is-this-topic/update/","result":{"pageContext":{"chapter":{"id":"161f4a52-fee2-5c49-b8b5-e7e55898959d","slug":"update","fullItemName":"Update","depth":2,"htmlHeader":"<!-- begin field 96800011-8029-4190-b594-9c9bb82f4e33 --><h2>Update</h2><!-- end field 96800011-8029-4190-b594-9c9bb82f4e33 -->","summary":null,"htmlStringContent":"<!-- begin item 2bf2afe2-aa50-4280-b1a4-f2c4bdfa43c6 --><!-- end item 2bf2afe2-aa50-4280-b1a4-f2c4bdfa43c6 -->","topic":{"id":"3964f7a0-31e0-5fbb-acd2-28c331f8537e","topicId":"00508bc9-f2ae-4b62-92b6-6813013390e7","topicName":"Sleep disorders - shift work and jet lag","slug":"sleep-disorders-shift-work-jet-lag","lastRevised":"Last revised in November 2019","chapters":[{"id":"75b83b6f-3a17-5dc7-aaaf-e1b6b03327b4","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a06c50c6-432a-5239-ac77-63d42196c27b","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e323be68-8cbf-5d0d-8e67-715bbd68f4fe","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"3e71c356-1580-53be-a318-f61bddebbe31","slug":"changes","fullItemName":"Changes"},{"id":"161f4a52-fee2-5c49-b8b5-e7e55898959d","slug":"update","fullItemName":"Update"}]},{"id":"2410dfe4-334f-5bb0-bb78-718734524edd","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"1818b676-b05b-5c62-bde4-d5a491874e58","slug":"goals","fullItemName":"Goals"},{"id":"837249d3-d073-5636-81eb-cbae636e72f8","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"843d7f1a-ff5e-586e-9f78-741b1d60fd7c","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"d7031860-ccff-5bce-990d-2caf8637d96f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a7cc02c5-b610-55a2-95fe-f0529b8cd790","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"19065e02-2191-50f8-a226-fb5f03a13bb9","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"22d71374-a8f6-57e2-8b56-695bcfd2de86","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"132f5ec4-065d-54c9-9f83-4903e72f947e","slug":"definition","fullItemName":"Definition"},{"id":"d4c20af9-820c-52a4-a7e3-24612493b406","slug":"prevalence","fullItemName":"Prevalence"},{"id":"eff0d9ba-562f-5d45-b87c-b9d29631adb5","slug":"complications","fullItemName":"Complications"}]},{"id":"1a1d5c53-1d0d-509a-8d09-4d3ba1ab3eff","fullItemName":"Management","slug":"management","subChapters":[{"id":"aadd62d1-be2a-511a-ad8b-a4e54db4850f","slug":"shift-work","fullItemName":"Scenario: Shift work"},{"id":"8c01af16-f5e8-5548-89ed-df600c5a74fa","slug":"jet-lag","fullItemName":"Scenario: Jet lag"}]},{"id":"af4ba3a4-9d3c-5bb7-9545-85d24a3010e2","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"78bdc2ca-d8fb-5813-be5c-b8897ac981f2","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"f79c6ed5-1d18-5084-9514-909d4e727748","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"d3e7f50a-efbb-52e8-9921-3054e9b6e536","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"8fecd819-5bdd-5ea4-9593-3d567a7a852e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c57fad3e-eebd-5ee5-94b5-8b2f5e782cbf","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1dd09b4f-2ae0-5c12-9cf0-e1948bbbab77","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"4fdf9e4c-dd47-5c20-a29d-bbbc24b38b16","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e323be68-8cbf-5d0d-8e67-715bbd68f4fe","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"2dfc1833-c2c1-5f5f-b411-8b5cdb4fc345","slug":"new-evidence","fullItemName":"New evidence","depth":3,"htmlHeader":"<!-- begin field 8ce96936-eaf9-4271-a15f-b740266a839d --><h3>New evidence</h3><!-- end field 8ce96936-eaf9-4271-a15f-b740266a839d -->","summary":null,"htmlStringContent":"<!-- begin item ab069469-81e0-4655-9c7f-bea1354f61a6 --><!-- begin field 7e7611a1-68b9-4bbb-b042-b84ec191bdef --><h3>Evidence-based guidelines</h3><!-- end field 7e7611a1-68b9-4bbb-b042-b84ec191bdef --><!-- begin field 5cc864db-92b7-44a1-89b6-1e1cb40438b4 --><p>No new evidence-based guidelines since 1 January 2019.</p><!-- end field 5cc864db-92b7-44a1-89b6-1e1cb40438b4 --><!-- begin field 5f4a2883-8c2c-4b4a-acd2-cc31567aecfb --><h3>HTAs (Health Technology Assessments)</h3><!-- end field 5f4a2883-8c2c-4b4a-acd2-cc31567aecfb --><!-- begin field c8b691c7-b95c-4a1c-ae45-52d5705f60c5 --><p>No new HTAs since 1 January 2019.</p><!-- end field c8b691c7-b95c-4a1c-ae45-52d5705f60c5 --><!-- begin field ee725c7c-b129-430c-b57b-ccb14d1ee0be --><h3>Economic appraisals</h3><!-- end field ee725c7c-b129-430c-b57b-ccb14d1ee0be --><!-- begin field 28b5ba76-6dc1-4521-84f7-94ef2be090b4 --><p>No new economic appraisals relevant to England since 1 January 2019.</p><!-- end field 28b5ba76-6dc1-4521-84f7-94ef2be090b4 --><!-- begin field cc899553-25f2-4692-80d4-d50a763cd634 --><h3>Systematic reviews and meta-analyses</h3><!-- end field cc899553-25f2-4692-80d4-d50a763cd634 --><!-- begin field 4d804b7d-2041-4e91-96a7-f5df2e21595e --><p>No new systematic reviews or meta-analyses since 1 January 2019.</p><!-- end field 4d804b7d-2041-4e91-96a7-f5df2e21595e --><!-- begin field 8bd90ccf-66fb-40f5-a4b1-6bea6c84af7f --><h3>Primary evidence</h3><!-- end field 8bd90ccf-66fb-40f5-a4b1-6bea6c84af7f --><!-- begin field 04d4f179-c8a5-49dc-9d98-ff9a0604401e --><p>No new randomized controlled trials published in the major journals since 1 January 2019.</p><!-- end field 04d4f179-c8a5-49dc-9d98-ff9a0604401e --><!-- end item ab069469-81e0-4655-9c7f-bea1354f61a6 -->","subChapters":[]},{"id":"2ca7eb39-cc88-5d6b-b73d-2bd9104c93fb","slug":"new-policies","fullItemName":"New policies","depth":3,"htmlHeader":"<!-- begin field 77fc8064-eb21-45b1-a38b-d4089b4dd311 --><h3>New policies</h3><!-- end field 77fc8064-eb21-45b1-a38b-d4089b4dd311 -->","summary":null,"htmlStringContent":"<!-- begin item 50190517-a699-4056-b0fd-65b7cf735c7f --><!-- begin field e041f868-b004-4eff-9044-29e5ecbf1280 --><p>No new national policies or guidelines since 1 January 2019.</p><!-- end field e041f868-b004-4eff-9044-29e5ecbf1280 --><!-- end item 50190517-a699-4056-b0fd-65b7cf735c7f -->","subChapters":[]},{"id":"3d4ed875-b183-5ae6-b906-4bc391ed6300","slug":"new-safety-alerts","fullItemName":"New safety alerts","depth":3,"htmlHeader":"<!-- begin field 0109e951-ef6c-4676-8a2a-f8fba2ad5d9a --><h3>New safety alerts</h3><!-- end field 0109e951-ef6c-4676-8a2a-f8fba2ad5d9a -->","summary":null,"htmlStringContent":"<!-- begin item ba0bb94a-043a-4561-a042-26656b221477 --><!-- begin field e5d96c6e-daf1-4e75-b877-9c4d811ed9ba --><p>No new safety alerts since 1 January 2019.</p><!-- end field e5d96c6e-daf1-4e75-b877-9c4d811ed9ba --><!-- end item ba0bb94a-043a-4561-a042-26656b221477 -->","subChapters":[]},{"id":"8cae9765-8b07-564a-980f-cbf7833cd7b1","slug":"changes-in-product-availability","fullItemName":"Changes in product availability","depth":3,"htmlHeader":"<!-- begin field 2664ceec-1f8d-4d4b-bd8c-1efc8b03caa8 --><h3>Changes in product availability</h3><!-- end field 2664ceec-1f8d-4d4b-bd8c-1efc8b03caa8 -->","summary":null,"htmlStringContent":"<!-- begin item e9c1ab9d-7e3e-4310-8e32-8f82b835b5c6 --><!-- begin field 7e8d2b74-7962-4c64-9cb6-aa81009dd182 --><ul><li>Melatonin 1mg/ml oral solution is licensed for short-term treatment of jet-lag in adults. The standard dose is 3 mg daily for a maximum of 5 days. The first dose should be taken on arrival at destination at the habitual bed-time. See more <a href=\"https://www.medicines.org.uk/emc/product/10419\" data-hyperlink-id=\"2af16726-396c-4fc8-ad9e-aa81009e044d\">here</a>. </li><li>Melatonin 3 mg film-coated tablets are licensed for short-term treatment of jet-lag in adults. The standard dose is 3 mg daily for a maximum of 5 days. The first dose should be taken on arrival at destination at the habitual bed-time. See more <a href=\"https://www.medicines.org.uk/emc/product/10405/smpc\" data-hyperlink-id=\"60df8e25-9d51-414e-8001-aa8100d2b9ee\">here</a>. </li><li>Melatonin Pharma Nord 3 mg film-coated tablets. This is licensed for the short-term treatment of jet-lag in adults. The standard dose is 3 mg daily for a maximum of 5 days. The dose may be increased to 6 mg if the standard dose does not adequately alleviate symptoms. See more <a href=\"https://www.medicines.org.uk/emc/product/11018/smpc\" data-hyperlink-id=\"08dfab57-d516-45bb-aa0a-ab5000c3b6ea\">here</a>.</li><li>Syncrodin (melatonin) 3 mg film-coated tablets are licensed for short-term treatment of jet lag in adults. The standard dose is 3 mg (1 tablet) daily for a maximum of 5 days. The first dose should be taken on arrival at destination at the habitual bedtime. See more <a href=\"https://www.medicines.org.uk/emc/product/11772/smpc\" data-hyperlink-id=\"3577ef64-0306-464f-82b0-ac4100b473fc\">here</a>.</li><li>Melatonin 3 and 5 mg hard capsules are licensed for short-term treatment of jet-lag in adults. See more <a href=\"https://www.medicines.org.uk/emc/product/11966/smpc\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"fa0fd66c-9d09-40e4-8695-ac9500b73930\">here</a>.</li></ul><!-- end field 7e8d2b74-7962-4c64-9cb6-aa81009dd182 --><!-- end item e9c1ab9d-7e3e-4310-8e32-8f82b835b5c6 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}